Cargando…
Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers
Cancer patients receiving anthracycline-based chemotherapy are at risk to develop life-threatening chronic cardiotoxicity with the pathophysiological mechanism of action not fully understood. Besides the most common hypothesis that anthracycline-induced congestive heart failure (CHF) is mainly cause...
Autores principales: | Henninger, Christian, Fritz, Gerhard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386353/ https://www.ncbi.nlm.nih.gov/pubmed/28102848 http://dx.doi.org/10.1038/cddis.2016.418 |
Ejemplares similares
-
Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity
por: Huelsenbeck, J, et al.
Publicado: (2011) -
Rho GTPases: Novel Players in the Regulation of the DNA Damage Response?
por: Fritz, Gerhard, et al.
Publicado: (2015) -
Mister Heartbreak
por: Anderson, Laurie, 1947-
Publicado: (1985) -
COVID HEARTBREAK
por: Anees, Moneba, et al.
Publicado: (2022) -
Anthracycline Chemotherapy and Cardiotoxicity
por: McGowan, John V, et al.
Publicado: (2017)